Friday, March 27, 2020 3:12:14 PM
I am out.
1) no PR so far
2) many offerings
4) too much dilution, that means so many screwed of this for so long.
3) distribution is not from direct developer
5) FDA approval required is for developer not aytu this means many competitors and also aytu can do nothing to push.
6) I covered my losses. Wasted too much life on this.
7) I know this will spin up after developer approval, I left few stocks which i earned so far.
8) many here talk about dilution but they are the actual diluters.
9) too much fake data keep posting again and again.
10) doesn't make sense why the developer have so many distribution points. China always wins in mathematics.
11) govt not interested in reactive approach.
I am thank ful to each and everyone.
Gba
1) no PR so far
2) many offerings
4) too much dilution, that means so many screwed of this for so long.
3) distribution is not from direct developer
5) FDA approval required is for developer not aytu this means many competitors and also aytu can do nothing to push.
6) I covered my losses. Wasted too much life on this.
7) I know this will spin up after developer approval, I left few stocks which i earned so far.
8) many here talk about dilution but they are the actual diluters.
9) too much fake data keep posting again and again.
10) doesn't make sense why the developer have so many distribution points. China always wins in mathematics.
11) govt not interested in reactive approach.
I am thank ful to each and everyone.
Gba
Recent AYTU News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:08:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/03/2026 09:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:05:35 PM
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results • ACCESS Newswire • 02/03/2026 09:05:00 PM
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 • ACCESS Newswire • 01/27/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:29 PM
- Aytu BioPharma Recaps Investor Day Held on January 20, 2026 • ACCESS Newswire • 01/20/2026 09:05:00 PM
- Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA • ACCESS Newswire • 01/20/2026 02:00:00 PM
- Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 • ACCESS Newswire • 01/13/2026 09:15:00 PM
- Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City • ACCESS Newswire • 01/12/2026 01:00:00 PM
- Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City • ACCESS Newswire • 12/18/2025 02:00:00 PM
- Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults • ACCESS Newswire • 12/15/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 09:05:23 PM
- Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference • ACCESS Newswire • 11/24/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 06:26:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:11:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:08:28 PM
- Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results • ACCESS Newswire • 11/13/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:35:20 PM
- Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 • ACCESS Newswire • 11/05/2025 09:05:00 PM
- Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) • ACCESS Newswire • 10/28/2025 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/24/2025 08:03:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/24/2025 08:02:41 PM
- Aytu BioPharma to Present at Upcoming October 2025 Conferences • ACCESS Newswire • 10/10/2025 01:00:00 PM
